Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Translational Medical Oncology

Prof. Dr. Stefan Fröhling

Multiparameter immunofluorescence image of clear cell sarcoma tissue

The Division of Translational Medical Oncology, established in 2019, has two overarching goals. First, investigators in the laboratory use functional and structural genetic approaches to gain insights into cancer biology that can be translated into novel diagnostic and therapeutic strategies. Second, clinically oriented investigators are working within prospective programs to generate comprehensive molecular portraits of large numbers of human cancers and use the results to inform clinical action – both at the level of individual patients and in the context of academically initiated trials – while feeding results back into exploratory research projects aimed at improving functional and mechanistic understanding of cancers. In keeping with these forward- and reverse-translational efforts at the interface between experimental cancer research and clinical application, which have a particular focus on the large and underserved group of rare cancers, the division's researchers represent multiple career paths and stages (postdoctoral scientists, Ph.D., M.Sc., and B.Sc. students; oncologists and M.D. students) and are supported by research technicians, study nurses, documentation staff, and dedicated administrative, data management, and scientific coordination teams.


Prof. Dr. Stefan Fröhling
Translational Medical Oncology (B340)
Deutsches Krebsforschungszentrum
und Nationales Centrum für Tumorerkrankungen (NCT)
Im Neuenheimer Feld 460
69120 Heidelberg
Tel: +49 +49 6221 56 6990

Selected Publications

  • Jahn A,* Rump A,* Widmann TJ,* Heining C, … , Hübschmann D, Fröhling S,* Glimm H,* Schröck E,* Klink B.* Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Ann Oncol 33:1186-1199 (2022).
  • Möhrmann L,* Werner M,* Ole? M,* Mock A,* Uhrig S,* Jahn A, … , Heining C, Fröhling S,* Glimm H.* Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nat Commun 13:4485 (2022).
  • Horak P*, Heining C,* Kreutzfeldt S,* Hutter B,* Mock A, … , Weichert W, Glimm H,* Fröhling S.* Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11:2780-2795 (2021).
  • Ronellenfitsch MW, … , Mittelbronn M, Steinbach JP,* Reuss DE,* Glimm H,* Stenzinger A,* Fröhling S.* Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. J Clin Invest 130:2488-2495 (2020).
to top
powered by webEdition CMS